Response to: 'Correspondence on 'Interleukin-6 blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: A case-control study' by Potere et al' by Buckley

Nicola Potere; Marcello di Nisio; Donatella Cibelli; Rosa Scurti; Antonella Frattari; Ettore Porreca; Antonio Abbate; Giustino Parruti

doi:10.1136/annrheumdis-2020-218715

Response to: 'Correspondence on 'Interleukin-6 blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: A case-control study' by Potere et al' by Buckley

Nicola Potere
, Marcello di Nisio
, Donatella Cibelli
, Rosa Scurti
, Antonella Frattari
, Ettore Porreca
, Antonio Abbate
, Giustino Parruti

Gabriele d'Annunzio University
Virginia Commonwealth University
Pescara General Hospital

Research output: Contribution to journal › Comment/Letter to the editor › Academic

26 Downloads (Pure)

Original language	English
Article number	e195
Journal	Annals of the rheumatic diseases
Volume	81
Issue number	10
Early online date	2022
DOIs	https://doi.org/10.1136/annrheumdis-2020-218715
Publication status	Published - 1 Sept 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

biological therapy
cytokines
glucocorticoids
inflammation

Access to Document

10.1136/annrheumdis-2020-218715

Response-to.pdfFinal published version, 288 KBLicence: CC BY

Cite this

Potere, N., di Nisio, M., Cibelli, D., Scurti, R., Frattari, A., Porreca, E., Abbate, A., & Parruti, G. (2022). Response to: 'Correspondence on 'Interleukin-6 blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: A case-control study' by Potere et al' by Buckley. Annals of the rheumatic diseases, 81(10), Article e195. https://doi.org/10.1136/annrheumdis-2020-218715

@article{420bdee20f9347f89b06ee7bf44afdf1,

title = "Response to: 'Correspondence on 'Interleukin-6 blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: A case-control study' by Potere et al' by Buckley",

keywords = "biological therapy, cytokines, glucocorticoids, inflammation",

author = "Nicola Potere and \{di Nisio\}, Marcello and Donatella Cibelli and Rosa Scurti and Antonella Frattari and Ettore Porreca and Antonio Abbate and Giustino Parruti",

year = "2022",

month = sep,

day = "1",

doi = "10.1136/annrheumdis-2020-218715",

language = "English",

volume = "81",

journal = "Annals of the rheumatic diseases",

issn = "0003-4967",

publisher = "BMJ Publishing Group",

number = "10",

}

Potere, N, di Nisio, M, Cibelli, D, Scurti, R, Frattari, A, Porreca, E, Abbate, A & Parruti, G 2022, 'Response to: 'Correspondence on 'Interleukin-6 blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: A case-control study' by Potere et al' by Buckley', Annals of the rheumatic diseases, vol. 81, no. 10, e195. https://doi.org/10.1136/annrheumdis-2020-218715

Response to: 'Correspondence on 'Interleukin-6 blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: A case-control study' by Potere et al' by Buckley. / Potere, Nicola; di Nisio, Marcello; Cibelli, Donatella et al.
In: Annals of the rheumatic diseases, Vol. 81, No. 10, e195, 01.09.2022.

Research output: Contribution to journal › Comment/Letter to the editor › Academic

TY - JOUR

T1 - Response to

T2 - 'Correspondence on 'Interleukin-6 blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: A case-control study' by Potere et al' by Buckley

AU - Potere, Nicola

AU - di Nisio, Marcello

AU - Cibelli, Donatella

AU - Scurti, Rosa

AU - Frattari, Antonella

AU - Porreca, Ettore

AU - Abbate, Antonio

AU - Parruti, Giustino

PY - 2022/9/1

Y1 - 2022/9/1

KW - biological therapy

KW - cytokines

KW - glucocorticoids

KW - inflammation

UR - https://www.scopus.com/pages/publications/85135201765

U2 - 10.1136/annrheumdis-2020-218715

DO - 10.1136/annrheumdis-2020-218715

M3 - Comment/Letter to the editor

C2 - 32873552

SN - 0003-4967

VL - 81

JO - Annals of the rheumatic diseases

JF - Annals of the rheumatic diseases

IS - 10

M1 - e195

ER -

Response to: 'Correspondence on 'Interleukin-6 blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: A case-control study' by Potere et al' by Buckley

UN SDGs

Keywords

Access to Document

Other files and links

Cite this